Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment.
Overview
Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce pain, fever and inflammation chiefly through inhibition of cyclooxygenase-dependent prostaglandin production. Selection depends on indication, duration, cardiovascular risk, prior ulcer/bleeding, kidney function, age, pregnancy and interactions [1,2].
Chemical and pharmacologic classification
- Salicylates: aspirin, which irreversibly acetylates COX in platelets.
- Propionic acids: ibuprofen, naproxen, ketoprofen and flurbiprofen.
- Acetic acids: diclofenac, indomethacin, ketorolac and sulindac.
- Oxicams (enolic acids): piroxicam and meloxicam.
- COX-2-selective coxibs: celecoxib and certain regionally approved agents.
- Other: nabumetone is a nonacidic prodrug.
The previous classification of ketorolac and diclofenac as pyrazolones was incorrect. Rofecoxib was withdrawn owing to cardiovascular risk and is not a routine current option [1].
Mechanisms and pharmacodynamics
COX-1 participates in gastric, platelet and renal prostanoid functions; COX-2 contributes to inflammation but also has physiologic roles. Inhibition reduces PGE2-mediated nociceptor sensitization and fever. Aspirin’s irreversible platelet COX-1 inhibition persists for the platelet lifespan, whereas most NSAIDs inhibit COX reversibly. COX-2 selectivity may reduce some GI toxicity but does not eliminate renal or cardiovascular risk [1].
Evidence-based applications
NSAIDs are used for musculoskeletal pain, osteoarthritis symptom control, primary dysmenorrhea, acute gout flares and other appropriately selected inflammatory conditions. Topical NSAIDs may be preferable for localized osteoarthritis, especially in patients vulnerable to systemic adverse effects. NSAIDs do not alter the underlying progression of rheumatoid arthritis or replace urate-lowering gout treatment. Use the lowest effective dose for the shortest necessary duration [1].
Gastrointestinal, kidney and cardiovascular harms
NSAIDs may cause dyspepsia, ulceration, gastrointestinal bleeding/perforation, salt and water retention, hypertension, acute kidney injury and worsening heart failure. Many nonaspirin NSAIDs carry warnings for myocardial infarction and stroke; the risk varies by drug, dose and patient. PPI gastroprotection can reduce upper GI complications in selected patients but does not prevent all intestinal or cardiovascular harm [1].
Pregnancy and fetal risks
The FDA advises avoiding NSAIDs from about 20 weeks of pregnancy unless specifically required by a clinician because fetal renal dysfunction may cause oligohydramnios. Between 20 and 30 weeks, if necessary, use the lowest effective dose for the shortest time and consider ultrasound assessment if beyond 48 hours. Avoid around 30 weeks and later because of premature fetal ductus arteriosus closure. This advice excludes clinician-directed low-dose aspirin used for certain pregnancy indications [2].
Interactions and safe use
Concurrent anticoagulants, antiplatelets, glucocorticoids or SSRIs can amplify bleeding risk. NSAIDs may reduce effectiveness of diuretics and renin-angiotensin blockers and worsen kidney injury, especially with dehydration (‘triple whammy’ of NSAID, ACEi/ARB and diuretic). Ibuprofen can interfere with low-dose aspirin’s platelet effect if timed improperly. Avoid dual systemic NSAIDs and assess allergies, asthma exacerbated by NSAIDs, kidney dysfunction and prior ulcer bleeding [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. Drug Safety Communication. 2020, updated 2022. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.